2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2073

Role of miRNA-21-5p As a Potential Biomarker for the Inflammation Pathway in Psoriatic Disease and Response to Methotrexate Treatment

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: L06

Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards

Late-Breaking Abstract Poster Session

9:00AM-11:00AM: Abstract Number: 2284

Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated on an Open-Label Extension of Trial JBT101-DM-001

Muscle Biology, Myositis and Myopathies Poster III: Treatment and Classification Criteria

9:00AM-11:00AM: Abstract Number: 2565

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2191

Safety of Ultrasound-Guided Injections Using Local Puncture Site Sterility

Health Services Research Poster III – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 2219

Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 2535

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CKD-506, a Novel, Histone Deacetylase 6 (HDAC6) Inhibitor, in Healthy Volunteers

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2539

SB4 Shows Comparable Short-Term Effectiveness to Its Etanercept Originator As First-Line Biologic Treatment for Patients with Rheumatoid Arthritis in Routine Clinical Care

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2707

Scleroderma Renal Crisis: The Association of High-Dose Steroids and Poor Outcome

Systemic Sclerosis and Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2766

Seasonal Variation in Incidence of Giant Cell Arteritis: A Population-Based Cohort Study

Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2168

Seasonal Variation in Incidence of Polymyalgia Rheumatica: A Population-Based

Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2556

Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2564

Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2585

Secukinumab Immunogenicity in Patients with Psoriatic Arthritis and Ankylosing Spondylitis during a 52-Week Treatment Period

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2562

Secukinumab Improves Grappa-Omeract Core Domains of Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].